Breaking Barriers With Basal Insulin Biosimilars in Type 2 Diabetes

Despite increases in the availability and effectiveness of other therapies, insulin remains an essential treatment for approximately 30 million people with type 2 diabetes worldwide. The development of biosimilars has created the potential for significant health care cost savings and may lead to gre...

Descripción completa

Detalles Bibliográficos
Autores principales: Heller, Simon, Raposo, João Filipe, Tofé, Santiago, Hanif, Wasim, Schroner, Zbynek, Down, Su, Blevins, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2023
Materias:
Feature Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10115621/
https://www.ncbi.nlm.nih.gov/pubmed/37092154
http://dx.doi.org/10.2337/cd22-0016
Descripción
Sumario:Despite increases in the availability and effectiveness of other therapies, insulin remains an essential treatment for approximately 30 million people with type 2 diabetes worldwide. The development of biosimilars has created the potential for significant health care cost savings and may lead to greater access to basal insulin for vast populations. In this review, we discuss evidence demonstrating equipoise between basal insulin biosimilars and the patented analogs they may replace.

Ejemplares similares